Table 2. Chemotherapy dose reductions over the first 12 weeks of treatment broken down by regimen and therapeutic agent, on line only.

	Arms A+C (no cetuximab)		Arm B (cetuximab)
	OxMdG	XELOX	OxMdG	XELOX	Total
Total N	203	333	102	166	804
Trial drug
5FU	48		31		79
% of patients with 5FU dose reduction	(24%)		(30%)		(26%a)
Capecitabine		65		60	125
% of patients with capecitabine dose reduction		(20%)		(36%)	(25%a)
Oxaliplatin	28	50	16	54	148
% of patients with oxaliplatin dose reduction	(14%)	(15%)	(16%)	(33%)	(18%)
Cetuximab			24	33	57
% of patients with cetuximab dose reduction			(24%)	(20%)	(21%a)
Any trial drug	57	73	45	81	256
% of patients with any trial drug dose reduction	(28%)	(22%)	(44%)	(49%)	(32%)

5FU=5-fluorouracil.

On line only.

^aDenominator is valid subjects only.